Compare KRP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRP | COLL |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2017 | 2015 |
| Metric | KRP | COLL |
|---|---|---|
| Price | $15.18 | $34.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.33 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 949.4K | 400.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | $333,830,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $6.88 | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $85.80 |
| Revenue Growth | 7.93 | ★ 23.62 |
| 52 Week Low | $11.31 | $28.74 |
| 52 Week High | $15.65 | $50.79 |
| Indicator | KRP | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 46.39 |
| Support Level | $14.10 | $31.56 |
| Resistance Level | $15.65 | $36.22 |
| Average True Range (ATR) | 0.32 | 1.67 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 71.84 | 11.85 |
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.